Table 1 |
|||
|
Characteristics of men that were included in the ED substudy by the 22 participating centres compared to those not included. |
|||
|
Nonparticipants (n = 463) |
Participants (n = 130) |
P value |
|
|
|
|||
|
Age (years) |
54.3 (46.0 to 64.1) |
52.3 (45.1 to 61.5) |
0.12 |
|
SSc duration by Raynaud's phenomenon (years) |
6.4 (3.4 to 11.7) |
7.0 (3.7 to 11.9) |
0.21 |
|
SSc duration by first non-Raynaud's symptom (years) |
5.4 (2.7 to 9.2) |
6.0 (3.0 to 10.3) |
0.20 |
|
Topoisomerase I (Scl70)-autoantibodiespositive |
42.8 |
46.7 |
0.44 |
|
Anti-centromere autoantibodies-positive |
14.9 |
15.7 |
0.82 |
|
U1RNP-positive |
6.5 |
4.7 |
0.51 |
|
RNA polymerase III-positive |
9.4 |
2.8 |
0.08 |
|
Diffuse SSc |
56.8 |
63.7 |
0.18 |
|
Puffy hands |
34.3 |
54.6 |
< 0.001* |
|
mRSS |
10 (4 to 16) |
13 (6 to 20) |
0.01* |
|
mRSS > 20 |
16.8 |
25.0 |
0.05 |
|
C-reactive protein elevation |
33.6 |
24.5 |
0.07 |
|
Digital ulcers |
34.7 |
44.0 |
0.04* |
|
Synovitis |
13.1 |
20.0 |
0.05 |
|
Joint contractures |
33.0 |
31.8 |
0.81 |
|
Tendon friction rubs |
10.2 |
10.0 |
0.94 |
|
Muscle weakness |
22.2 |
20.9 |
0.76 |
|
Muscle atrophy |
11.1 |
15.5 |
0.17 |
|
Creatine kinase elevation |
11.6 |
13.3 |
0.58 |
|
Oesophageal symptoms |
54.4 |
60.4 |
0.23 |
|
Stomach symptoms |
16.0 |
13.5 |
0.50 |
|
Intestinal symptoms |
18.8 |
12.6 |
0.11 |
|
Lung fibrosis on chest X-ray or HRCT |
60.4 |
56.7 |
0.59 |
|
Forced vital capacity (% predicted) |
89 (75 to 101) |
92 (81 to 103) |
0.36 |
|
Forced vital capacity < 80% |
32.2 |
23.3 |
0.10 |
|
DLCO (% predicted) |
66 (49 to 82) |
69 (55 to 88) |
0.05 |
|
DLCO < 80% |
71. |
59.1 |
0.01* |
|
PAPsys (mmHg) |
30 (25 to 37) |
27 (20 to 36) |
0.004* |
|
PAPsys > 40 mmHg |
22.3 |
19.4 |
0.51 |
|
Diastolic dysfunction |
20.4 |
18.8 |
0.70 |
|
Pericardial effusion |
7.1 |
5.7 |
0.64 |
|
Left ventricular ejection fraction < 60% |
25.1 |
20.0 |
0.31 |
|
Arterial hypertension |
21.5 |
23.6 |
0.75 |
|
Renal crisis |
3.3 |
4.5 |
0.50 |
|
Proteinuria |
8.6 |
9.4 |
0.79 |
|
EULAR SSc activity score |
1.5 (0.5 to 3.0) |
2 (0.5 to 3.5) |
0.27 |
|
High SSc activity (score ≥ 3) |
27.2 |
35.2 |
0.19 |
|
Hypocomplementaemia |
5.0 |
5.9 |
0.71 |
|
|
|||
|
Demographic parameters and disease characteristics from the EULAR Scleroderma Trial and Research database Data presented as median (interquartile range) or percentage. DLCO; diffusion capacity of the lung for carbon monoxide; HRCT, high resolution computed tomography; mRSS; modified Rodnan skin score; PAPsys; systolic pulmonary arterial pressure; SSc, systemic sclerosis. *Significant at P < 0.05. |
|||
|
Foocharoen et al. Arthritis Research & Therapy 2012 14:R37 doi:10.1186/ar3748 |
|||
